Evoke Pharma Stock Probability of Future Stock Price Finishing Over 24.85

EVOK Stock  USD 24.85  0.30  1.22%   
Evoke Pharma's future price is the expected price of Evoke Pharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Evoke Pharma performance during a given time horizon utilizing its historical volatility. Check out Evoke Pharma Analysis, Evoke Pharma Valuation, Evoke Pharma Correlation, Evoke Pharma Hype Analysis, Evoke Pharma Volatility, Evoke Pharma Price History as well as Evoke Pharma Performance.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.At this time, Evoke Pharma's Price Book Value Ratio is quite stable compared to the past year. Price To Book Ratio is expected to rise to 2.74 this year, although the value of Price Earnings To Growth Ratio will most likely fall to 0.02. Please specify Evoke Pharma's target price for which you would like Evoke Pharma odds to be computed.

Evoke Pharma Target Price Odds to finish over 24.85

The tendency of Evoke Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 24.85 90 days 24.85 
about 13.47
Based on a normal probability distribution, the odds of Evoke Pharma to move above the current price in 90 days from now is about 13.47 (This Evoke Pharma probability density function shows the probability of Evoke Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Evoke Pharma has a beta of 0.39 suggesting as returns on the market go up, Evoke Pharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Evoke Pharma will be expected to be much smaller as well. In addition to that Evoke Pharma has an alpha of 3.76, implying that it can generate a 3.76 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Evoke Pharma Price Density   
       Price  

Predictive Modules for Evoke Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Evoke Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
7.8223.6839.54
Details
Intrinsic
Valuation
LowRealHigh
4.3120.1736.03
Details
Naive
Forecast
LowNextHigh
10.9626.8342.69
Details
1 Analysts
Consensus
LowTargetHigh
16.3818.0019.98
Details

Evoke Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Evoke Pharma is not an exception. The market had few large corrections towards the Evoke Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Evoke Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Evoke Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
3.76
β
Beta against Dow Jones0.39
σ
Overall volatility
7.29
Ir
Information ratio 0.17

Evoke Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Evoke Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Evoke Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Evoke Pharma is way too risky over 90 days horizon
Evoke Pharma appears to be risky and price may revert if volatility continues
Evoke Pharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 10.25 M. Net Loss for the year was (5.35 M) with profit before overhead, payroll, taxes, and interest of 13.99 M.
Evoke Pharma currently holds about 13.45 M in cash with (5.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02.
Evoke Pharma has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Insider Trading

Evoke Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Evoke Stock often depends not only on the future outlook of the current and potential Evoke Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Evoke Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding1.9 M
Cash And Short Term Investments13.6 M

Evoke Pharma Technical Analysis

Evoke Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Evoke Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Evoke Pharma. In general, you should focus on analyzing Evoke Stock price patterns and their correlations with different microeconomic environments and drivers.

Evoke Pharma Predictive Forecast Models

Evoke Pharma's time-series forecasting models is one of many Evoke Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Evoke Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Evoke Pharma

Checking the ongoing alerts about Evoke Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Evoke Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Evoke Pharma is way too risky over 90 days horizon
Evoke Pharma appears to be risky and price may revert if volatility continues
Evoke Pharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 10.25 M. Net Loss for the year was (5.35 M) with profit before overhead, payroll, taxes, and interest of 13.99 M.
Evoke Pharma currently holds about 13.45 M in cash with (5.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02.
Evoke Pharma has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Insider Trading
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:
Check out Evoke Pharma Analysis, Evoke Pharma Valuation, Evoke Pharma Correlation, Evoke Pharma Hype Analysis, Evoke Pharma Volatility, Evoke Pharma Price History as well as Evoke Pharma Performance.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. Projected growth potential of Evoke fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Evoke Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.38)
Revenue Per Share
5.182
Quarterly Revenue Growth
0.614
Return On Assets
(0.22)
Return On Equity
(1.35)
Investors evaluate Evoke Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evoke Pharma's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Evoke Pharma's market price to deviate significantly from intrinsic value.
It's important to distinguish between Evoke Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evoke Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evoke Pharma's market price signifies the transaction level at which participants voluntarily complete trades.